Please assess the completion status of the following clinical trial:

Trial Title: Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Normal general cognitive function~* High Risk Group Only: Family history (1st degree relative) of AD~* Low Risk Group Only: No family history (1st or 2nd degree relative) of AD~* Visual and auditory acuity adequate for neuropsychological testing~Exclusion Criteria:~* Current or past history of~* neurological illnesses/conditions~* head trauma with significant loss of consciousness~* medical illnesses/conditions that may affect brain function~* severe psychiatric disorder~* substance abuse~* unstable or severe cardiovascular disease or asthmatic condition~* history of stroke or transient ischemic attack

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Donepezil HCL (Type: ACTIVE_COMPARATOR): Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo for 24 weeks.
- Control Group (Type: NO_INTERVENTION): Participants without a family history of AD will undergo the study evaluations but will not receive any study drug

Based on this trial design, predict the completion outcome and termination type (if applicable).